Tag
This article explores how PD-L1 and PD-L2 differentially regulate immune and lineage-specific programs in primary mediastinal large B-cell lymphoma, providing insights for tailored immunotherapy.
The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.
NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp
Immune checkpoint therapy has become a major advance in pediatric Hodgkin lymphoma and is now being actively tested across selected pediatric non-Hodgkin lymphomas with strong PD-L1 biology.
The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety p
